Successful pregnancy achieved by in vitro fertilization after fertility-preserving treatments in an infertile woman with borderline ovarian tumor and endometrial complex atypical hyperplasia: a case report

Both borderline ovarian tumors (BOTs) and complex atypical hyperplasia (CAH) are low malignant disease of the female reproductive system, which can be treated with fertility-preserving treatments for women of reproductive age. Assisted reproductive technology (ART) is used to achieve pregnancy in infertile women. Although treatments for the isolated disease have some guidelines, protocol making is not that simple when abnormalities coexist. Here, a case of patient with BOT, a history of CAH, and infertility is presented. After fertility-preserving surgery and in-vitro fertilization and embryo transfer (IVF-ET) , the patient successfully achieved a twin pregnancy leading to term live birth. The treatment process towards the complex situation is available for future reference. Consent: We present the first case with abnormalities co-existence and the process of combined treatment is effective and available for future reference.

Borderline ovarian tumors; Complex atypical hyperplasia; Laparoscopy; Assisted reproductive technology.

[1] Vasconcelos I., de Sousa Mendes M.: “Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk”. Eur. J. Cancer, 2015, 51, 620.

[2] Darai E., Fauvet R., Uzan C., Gouy S., Duvillard P., Morice P.: “Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options”. Hum. Reprod. Update, 2013, 19, 151.

[3] Gunderson C.C., Fader A.N., Carson K.A., Bristow R.E.: “Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review”. Gynecol. Oncol., 2012, 125, 477.

[4] Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K.: “Regression, relapse, and live birth rates with fertilitysparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis”. Am. J. Obstet. Gynecol., 2012, 207, 266.e1.

[5] Gokcu M., Gungorduk K., Asicioglu O., Cetinkaya N., Gungor T., Pakay G., et al.: “Borderline ovarian tumors: clinical characteristics, management, and outcomes - a multicenter study”. J. Ovarian Res., 2016, 9, 66.

[6] Trimble C.L., Kosary C., Trimble E.L.: “Long-term survival and patterns of care in women with ovarian tumors of low malignant potential”. Gynecol. Oncol., 2002, 86, 34.

[7] Iglesias D.A., Ramirez P.T.: “Role of minimally invasive surgery in staging of ovarian cancer”. Curr. Treat. Options Oncol., 2011, 12, 217.

[8] Siristatidis C., Sergentanis T.N., Kanavidis P., Trivella M., Sotiraki M., Mavromatis I., et al.: “Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta-analysis”. Hum. Reprod. Update, 2013, 19, 105.

[9] Stewart L.M., Holman C.D., Finn J.C., Preen D.B., Hart R.: “In vitro fertilization is associated with an increased risk of borderline ovarian tumours”. Gynecol. Oncol., 2013, 129, 372.

[10] Huusom L.D., Frederiksen K., Hogdall E.V., Glud E., Christensen L., Hogdall C.K., et al.: “Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study”. Cancer Causes Control, 2006, 17, 821.

[11] Basille C., Olivennes F., Le Calvez J., Beron-Gaillard N., Meduri G., Lhomme C., et al.: “Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours”. Hum. Reprod., 2006, 21, 3241.

[12] Vasconcelos I., Darb-Esfahani S., Sehouli J.: “Serous and mucinous borderline ovarian tumours: differences in clinical presentation, highrisk histopathological features, and lethal recurrence rates”. BJOG, 2016, 123, 498.

[13] Nam J.H.: ‘Borderline ovarian tumors and fertility”. Curr. Opin. Obstet. Gynecol., 2010, 22, 227.

[14] Lambalk C.B., Banga F.R., Huirne J.A., Toftager M., Pinborg A., Homburg R., et al.: “GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type”. Hum. Reprod. Update, 2017, 23, 560.

[15] Suh-Burgmann E., Hung Y.Y., Armstrong M.A.: “Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage”. Obstet. Gynecol., 2009, 114, 523.

[16] Zhou R., Yang Y., Lu Q., Wang J., Miao Y., Wang S., et al.: “Prognostic factors of oncological and reproductive outcomes in fertilitysparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients”. Gynecol. Oncol., 2015, 139, 424.

[17] Kudesia R., Singer T., Caputo T.A., Holcomb K.M., Kligman I., Rosenwaks Z., et al.: “Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma”. Am. J. Obstet. Gynecol., 2014, 210, 255.e1.